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Objective : Routine use of prophylactic antiepileptic drugs (AED) has been 
debated. We retrospectively evaluated the effects of prophylactic AED on 
clinical outcomes in patients with a good clinical grade suffering from 
aneurysmal subarachnoid hemorrhage (aSAH).
Materials and Methods : Between September 2012 and December 2014, 
84 patients who met the following criteria were included: (1) presence of 
a ruptured aneurysm; (2) Hunt-Hess grade 1, 2, or 3; and (3) without 
seizure presentation. Patients were divided into two groups; the AED 
group (n = 44) and the no AED group (n = 40). Clinical data and out-
comes were compared between the two groups.
Results : Prophylactic AEDs were used more frequently in patients who 
underwent microsurgery (84.1%) compared to those who underwent en-
dovascular surgery (15.9%, p < 0.001). Regardless of prophylactic AED 
use, seizure episodes were not observed during the six-month follow-up 
period. No statistical difference in clinical outcomes at discharge (p = 
0.607) and after six months of follow-up (p = 0.178) were between the 
two groups. After six months, however, favorable outcomes in the no 
AED group tended to increase and poor outcomes tended to decrease.
Conclusion : No difference in the clinical outcomes and systemic compli-
cations at discharge and after six months of follow-up was observed be-
tween the two groups. However, favorable outcomes in the no AED 
group showed a slight increase after six months. These findings suggest 
that discontinuation of the current practice of using prophylactic AED 
might be recommended in patients with a good clinical grade.
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INTRODUCTION
Administration of antiepileptic drugs (AED) in the 
setting of aneurysmal subarachnoid hemorrhage (aSAH) 
has become routine in the hope of achieving better 
outcomes for patients. Previous studies have reported 
a high incidence of seizures in the setting of aSAH 
(12.5-22%).4)23) AED use is standard practice for pre-
vention of seizure episodes, which can cause hypoxic 
brain injury or subsequent electrical field suppression, 
possibly delaying recovery or adversely influencing 
the natural course of the disease. However, prophy-
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lactic AEDs have been associated with side effects in-
cluding behavioral and cognitive impairments,1)16) and 
complicated brain hemorrhage. Therefore, more so-
phisticated guidelines for treatment or prevention of 
seizure due to SAH are needed.
According to the current guidelines,8)22) prophylactic 
AED may be considered for patients with known risk 
factors for seizure, such as poor clinical grade 
(Hunt-Hess [HH] grade 4 or 5), intraparenchymal 
hematoma, microsurgical clipping, postoperative hem-
atoma, aneurysms of the middle cerebral artery, and 
cerebral ischemia.5)11)13)14)19) Among these risk factors, 
the most comprehensive and predictive entity is poor 
clinical grade such as in cases of middle cerebral arte-
rial aneurysm with intraparenchymal hematoma re-
quiring microsurgical clipping combined with decom-
pressive surgery. However, the use of prophylactic 
AED in patients with a good clinical grade is not rec-
ommended by the guidelines but used currently in 
our clinical practice. Thus, we retrospectively eval-
uated the effects of prophylactic AED on clinical out-
comes in patients with a good clinical grade suffering 
from aSAH.
MATERIALS AND METHODS
This retrospective study was approved by our in-
stitutional review board, and the requirement for in-
formed consent was waived. A total of 84 patients 
were enrolled from a database of 133 patients with 
aSAH who underwent either microsurgery or endo-
vascular surgery between September 2012 and 
December 2014. All included patients met the follow-
ing criteria: (1) presence of a ruptured intracranial 
aneurysm on computed tomography angiography or 
magnetic resonance angiography; (2) HH grade 1, 2, 
or 3 on admission; and (3) without seizure presentation. 
The remaining 49 patients from the database were ex-
cluded for the following reasons: (1) onset seizures (n 
= 4); (2) HH grade 4 or 5 on admission (n = 38); (3) 
history of previous seizure taking AED (n = 2); and 
(4) loss to follow-up (n = 5). Included patients were 
divided into two groups according to the usage of 
prophylactic AED; the AED group (n = 44) and the no 
AED group (n = 40). Patients were prescribed 1000 
mg of levetiracetam or 900 mg valproic acid daily for 
at least 6 months (6 to 12 months).
Clinical data, including age, gender, initial HH grade, 
Fisher grade, hypertension, diabetes, dyslipidemia, 
smoking, treatment modality, hydrocephalus, external 
ventricular drainage, shunt, symptomatic vasospasm, 
procedure related complications, systemic complications 
and aneurysm characteristics (location, shape, size, and 
neck diameter), were reviewed and compared between 
the two groups. Procedure related complications were 
defined as new neurological deterioration related to 
treatment modality (microsurgery or endovascular 
surgery) or complications requiring additional procedures. 
Systemic complications were defined as major medical 
complications, such as infectious conditions (pneumonia 
or urinary tract infection), hepatic dysfunction, renal 
dysfunction, pulmonary complications (atelectasis, pul-
monary effusion, or pulmonary edema), cardiology 
complications (myocardial infarction, arrhythmia, or 
heart failure), and electrolyte imbalance (hyponatremia 
or hypernatremia), affecting clinical outcomes. The 
patients' clinical outcomes were evaluated at discharge 
and after six months of follow-up using the modified 
Rankin scale (mRS). A favorable outcome was defined 
as mRS of 0 to 2 and a poor outcome as mRS of 3 to 
6. No difference in overall medical management and 
general care in the acute period was observed be-
tween the two groups.
All statistical analyses were consulted to a biostatistician 
and performed using SPSS 22.0 (SPSS Inc., Chicago, IL, 
USA). Variables are expressed as the mean ± SD, or the 
number of patients (%), as appropriate. Student's t-tests 
were used for numeric variables, and Fisher's exact tests 
for nominal variables. Logistic regression analysis was 
performed on variables with an unadjusted effect and 
a p-value < 0.10 in univariate analysis to determine 
risk factors associated with poor outcomes in the AED 
group. A p-value < 0.05 for a 95% confidence interval 
(CI) was considered statistically significant.
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AED group (n = 44) No AED group (n = 40) p value
Age (mean ± SD) 52.8 ± 12.7 52.4 ± 13.9 0.906
Gender
Male
Female
21 (47.7%)
23 (52.3%)
20 (50.0%)
20 (50.0%)
0.835
AED
Levetiracetam
Valproic acid
Valproic acid
9 (20.5%)
NA
NA
NA
Underlying disease
HTN
DM
Dyslipidemia
Smoking
9 (20.5%)
3 (6.8%)
6 (13.6%)
8 (18.2%)
8 (20.0%)
3 (7.5%)
4 (10.0%)
6 (15.0%)
0.673
Aneurysm location
ICA
ACA
MCA
Posterior circulation
10 (22.7%)
15 (34.1%)
17 (38.6%)
2 (4.5%)
11 (27.5%)
10 (25.0%)
9 (22.5%)
10 (25.0%)
0.104
Aneurysm shape
Saccular
Dissecting
44 (100%)
0 (0%)
36 (90.0%)
4 (10.0%)
0.032
Aneurysm size (mm, mean ± SD) 6.32 ± 2.94 7.65 ± 5.59 0.177
Initial HHG
1
2
3
1 (2.3%)
29 (65.9%)
18 (40.9%)
0 (0.0%)
22 (55.0%)
14 (35.0%)
0.990
Fisher grade
1
2
3
4
0 (0.0%)
7 (15.9%)
29 (65.9%)
8 (18.2%)
0 (0.0%)
7 (17.5%)
26 (65.0%)
7 (17.5%)
0.980
EVD or Shunt 9 (20.5%) 5 (12.5%) 0.298
Hydrocephalus 10 (22.7%) 4 (10%) 0.254
Symptomatic vasospasm 7 (15.9%) 5 (12.5%) 0.772
Procedure related complication 3 (6.8%) 1 (2.5%) 0.621
Systemic complication 9 (20.5%) 2 (5.0%) 0.106
Treatment modality
Microsurgery
Endovascular surgery
37 (84.1%)
7 (15.9%)
7 (17.5%)
33 (82.5%)
< 0.001
Clinical outcome at discharge
Favorable (mRS 0~2)
Poor (mRS 3~6)
38 (86.4%)
6 (13.6%)
36 (90.0%)
4 (10.0%)
0.607
Clinical outcome on 6-month
Favorable (mRS 0~2)
Poor (mRS 3~6)
38 (86.4%)
6 (13.6%)
38 (95.0%)
2 (5.0%)
0.178
ACA = anterior cerebral artery; AED = antiepileptic drug; DM = diabetes mellitus; EVD = external ventricular drainage; HTN = hypertension; 
ICA = internal carotid artery; MCA = middle cerebral artery; NA = not applicable; mRS = modified Rankin Scale; SD = standard deviation
Table 1. Clinical data and outcomes of the two groups
RESULTS
The clinical characteristics and outcomes of the 84 
patients according to the use of prophylactic AED are 
summarized in Table 1. The mean age was 52.6 ± 13.3 
years (range: 25-86 years). Age, gender, underlying 
disease, and aneurysm profiles were not statistically 
different between the two groups. There was no oc-
currence of seizure episodes in any of the included 
patients during admission or follow-up. Treatment 
modality differed significantly between the two 
groups; prophylactic AED was used more frequently 
in patients who underwent microsurgery (84.1%) 
compared to those who underwent endovascular sur-
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Systemic problem AED (n = 44) No AED (n = 40)
Pneumonia 3 (6.8%) 1 (2.5%)
Pulmonary system 1 (2.3%) 1 (2.5%)
Electrolyte imbalance 2 (4.5%) 0 (0%)
Cardiology 2 (4.5%) 0 (0%)
Renal dysfunction 1 (2.3%) 0 (0%)
Total 9 (20.5%) 2 (5.0%)
AED = antiepileptic drug 
Table 2. Systemic complications in both groups
Fig. 1. Bar graph of the modified Rankin scale (mRS) showing clinical outcomes of the two groups at discharge. AED = antiepileptic 
drug.
gery (15.9%, p < 0.001). Aneurysm shape was also 
found to differ between the two groups (p = 0.032) 
because all dissecting aneurysms were treated by en-
dovascular surgery.
A total of nine systemic complications occurred with 
higher frequency (20.5%) in the AED group compared 
to the no AED group (5.0%). However, statistical sig-
nificance was not achieved (p = 0.106). The frequency 
of each complication is shown in Table 2. Pneumonia, 
in four patients, was the most common systemic 
complication. No identifiable psychiatric problem, de-
lirium, or hepatic dysfunction was observed even in 
patients treated with AED. Regardless of prophylactic 
AED use, there was no occurrence of seizure episodes 
in any patients (HH grade 1, 2, or 3) with a SAH dur-
ing six months of follow-up.
No statistical difference in clinical outcomes at dis-
charge and after six months of follow-up was ob-
served between the two groups (p = 0.607 and 0.178, 
respectively). At discharge, 38 (86.4%) of 44 patients 
in the AED group showed a favorable outcome with 
one death due to pneumonia sepsis whereas 36 
(90.0%) of 40 patients in the no AED group showed 
favorable outcomes without mortality (Fig. 1). After 
six months of follow-up, patients in the AED group 
did not show improved clinical outcomes. However, 
favorable outcomes of patients in the no AED group 
showed a slight increase to 95.0% and poor outcomes 
decreased to 5.0%.
Analysis of risk factors associated with poor out-
comes in the AED group is shown in Table 3. Logistic 
regression analysis showed that hydrocephalus (odds 
ratio [OR] = 14.286; 95% CI, 1.277 to 166.67; p = 0.031) 
and symptomatic vasospasm (OR = 9.615, 95% CI, 
1.088 to 83.333; p = 0.042) were independently asso-
ciated with poor outcomes in the AED group.
DISCUSSION
In the current study, seizure did not occur in aSAH 
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Favorable (n = 38) Poor (n = 6) P, Univariate P, Regression(OR, 95% CI)
Age (year, mean ± SD) 52.7 ± 12.6 52.8 ± 13.6 0.986
Gender
Male (n = 21)
Female (n = 23)
20
18
1
5
0.133
AED
Levetiracetam (n = 35)
Valproic acid (n = 9)
32
6
3
3
0.072
0.107 (0.053, 0.002-1.876)
Hypertension
Yes (n = 9)
No (n = 35)
7
31
2
4
0.409
Diabetes
Yes (n = 3)
No (n = 41)
3
35
0
6
0.999
Dyslipidemia
Yes (n = 6)
No (n = 38)
5
33
1
5
0.816
Smoking
Yes (n = 8)
No (n = 36)
8
30
0
6
0.999
Aneurysm location
ICA (n = 10)
ACA (n = 15)
MCA (n = 17)
Posterior circulation (n = 2)
7
13
17
1
3
2
1
0.59
0.244
0.998
0.624
Aneurysm size (mm, mean ± SD) 6.3 ± 3.0 6.4 ± 2.1 0.93
Hydrocephalus
Yes (n = 7)
No (n = 37)
3
35
4
2
0.003 0.031 (14.286, 1.277-166.667)
Symptomatic vasospasm
Yes (n = 10)
No (n = 34)
6
32
4
2
0.015 0.042 (9.615, 1.088-83.333)
Procedure related complication
Yes (n = 3)
No (n = 41)
2
36
1
5
0.33 0.641 (2.278, 0.071-71.429)
Systemic complication
Yes (n = 7)
No (n = 37)
5
33
2
4
0.228 0.134 (5.952, 0.576-62.500)
Treatment modlaity
Microsurgery (n = 37)
Endovascular surgery (n = 7)
33
5
4
2
0.228 0.454 (4.606, 0.085-250.555)
ACA = anterior cerebral artery; AED = antiepileptic drug; CI = confidence interval; ICA = internal carotid artery; MCA = middle cerebral 
artery; OR = odds ratio; SD = standard deviation 
Table 3. Risk factors associated with poor outcomes in the AED group
patients with a good clinical grade during admission 
or follow-up regardless of prophylactic AED use. At 
our institution, we tended to use prophylactic AED 
for patients who underwent microsurgery and pa-
tients with ruptured aneurysms of the anterior cere-
bral artery. However, our findings indicate that treat-
ment with AED had no effect on seizure prophylaxis. 
A number of retrospective series similar to ours have 
demonstrated no significant difference in terms of 
seizure outcome between groups with or without 
prophylaxis.3)6)9)15)18) In an analysis of four large trials, 
patients who received AED had an odds ratio of 1.56 
for worse outcomes after three months of follow-up, 
as well as increased risk for vasospasm, neurological 
deterioration, cerebral infarction, and elevated tem-
perature during hospitalization.18) In the current study, 
the clinical outcomes at discharge and after six months 
of follow-up were not statistically different between 
the two groups (p = 0.607 and 0.178, respectively). At 
discharge, 86.4% of patients in the AED group showed 
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a favorable outcome, but there was one death due to 
pneumonia. In the no AED group, 90.0% of patients 
showed favorable outcomes without mortality. However, 
after six months of follow-up, favorable outcomes of 
patients in the no AED group showed a slight in-
crease to 95.0% and poor outcomes decreased to 5.0%. 
In clinical practice, AED usage for patients with 
aSAH is generally accepted for prevention of seizure 
episodes. According to the current guidelines,8)22) 
however, prophylactic AED may be considered for 
patients with known risk factors for seizure, one of 
which is poor clinical grade (HH grade 4 or 5) on ini-
tial presentation. Unlike aSAH with a poor clinical 
grade, patients with a good clinical grade (HH grade 
1, 2, or 3) had relatively lower risk of developing seiz-
ure due to aneurysm rupture. In addition, routine use 
of AED in those patients has recently come under 
question.21) As reported in a systematic review, the 
rate of early postoperative seizure was 2.3% and the 
rate of late postoperative seizure was 5.5%.20) The 
average time to late seizure was 7.45 months. Patients 
who experienced a late seizure were more likely to 
undergo repair with microsurgery than endovascular 
surgery. They concluded that routine perioperative 
AED usage did not seem to prevent seizures after 
aSAH. However, it should be noted that seizures 
might occur years after aSAH and careful monitoring 
for late complications remains important.
In the current study, we realized that we tended to 
use prophylactic AED for patients who underwent 
microsurgery. In the International Subarachnoid 
Aneurysm trial (ISAT), patients treated with micro-
surgery had a significantly higher risk of late seizure 
than those treated with endovascular surgery.17) In a 
survey conducted by the American Association of 
Neurological Surgeons, 24% of neurosurgeons sur-
veyed routinely prescribed AED for three months af-
ter aSAH regardless of whether seizures occurred at 
presentation, in the hospital, or not at all.2)6)10)12) 
However, in a systematic review there was no sig-
nificant difference in the incidence of early and late 
seizure between patients treated with AED (3.0% and 
5.9%, respectively) and those not treated with AED 
(2.2% and 6.3%, respectively, p > 0.99).20)
From the risk factor analysis for poor outcomes in 
the AED group, hydrocephalus and symptomatic vas-
ospasm were found to be were well-known and un-
derstandable risk factors. Although the adverse effects 
of AEDs have not been well characterized in patients 
with aSAH, adverse effects due to phenytoin were re-
ported in 21.4% of patients.20) We used levetriacetam 
or valproic acid, and fortunately did not experience 
adverse effects.
There are several limitations to this study. First, it 
was a retrospective study based on our prospectively 
collected database with a small number of enrolled 
patients. Therefore the data do not represent the true 
incidence of late seizures. Second, we did not eval-
uate electroencephalograms (EEG), thus we could not 
determine the occurrence of non-convulsive seizures.
A previous study indicated that the incidence of 
non-convulsive seizure from intracranial hemorrhage 
is approximately 38%.7) However, as we enrolled 
only conscious patients with a good clinical grade, 
non-convulsive seizures would likely have been de-
tected clinically. Third, clinical outcomes of both groups 
might be affected by treatment modality, which de-
termined AED administration in our practice. This im-
balance in frequency of treatment modalities should 
have influenced clinical outcomes. Finally, cognitive func-
tion was not evaluated. The use of anticonvulsants could 
decrease intelligence. In patients with aSAH, however, 
evaluation of cognitive function might be incomplete, 
time-consuming, and lack specificity. Accordingly, we 
only measured clinical outcomes with the mRS.
CONCLUSION
No difference in clinical outcomes and systemic 
complications at discharge and after six months of fol-
low-up was observed between the two groups. However, 
favorable outcomes in the no AED group showed a 
slight increase after six months. Our findings suggest 
that discontinuation of the current practice of prophy-
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lactic AED use might be recommended in patients 
with a good clinical grade.
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